Moleculent
PrivateLast Round
Series A
Extension
Apr 30, 2026
Total Funding Raised
$46M
Momentum Score
50 /100
Company Overview
Moleculent is a biotechnology company that is developing a functional profiling platform to map cell-cell communication directly within clinical tissue. This technology aims to provide scientists with a deeper understanding of functional human biology and the cellular complexity of health and disease. By analyzing how cells interact and coordinate, the platform can offer insights into the signaling pathways and molecular mechanisms involved in conditions like cancer, potentially revealing how they respond to drugs. The company, founded by a team with experience at companies like Agilent and Perkin Elmer, secured $26 million in a Series A financing round in June 2024, led by ARCH Venture Partners and Eir Ventures. Moleculent's mission is to develop technology-enabled products based on new insights into the molecular foundations of human biology.
Sector
Healthcare & Life Sciences
Verticals
Biotech Equipment, Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Hardware + Subscription, Hardware Sales, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Moleculent Comps
Public and private peers based on sector, stage, and business model.
Moleculent Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Apr 30, 2026 | ||||
| Series A | Jun 11, 2024 |
Key People
Founding team and executive leadership
Moleculent Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Rubicon Healthcare Partners | Series A Extension |
| ARCH Venture Partners | Series A Extension |
| Eir Ventures | Series A Extension, Series A |
| ARCH Venture Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 30, 2026
$20M raised with Rubicon Healthcare Partners leading.
- Apr 30, 2026
Ole Dahlberg, Managing Partner at Rubicon Healthcare Partners, joins the Board of Directors.
Moleculent Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Moleculent's valuation, stock price, and market status.
